This multicenter trial compared the efficacy and safety of isradipine and enalapril in 160
patients with essential hypertension. Patients received isradipine or enalapril for 10 weeks …

Summary Isradipine, a 1, 4 dihydropyridine calcium channel antagonist, is a potent coronary
artery dilator that increases coronary blood flow with little effect on cardiac contractility …

In an open monocentric phase II study, 20 inpatients with hypertension were treated with a
single daily dose of nilvadipine for 3 weeks after a 1-week placebo washout phase. The …

Two ambulatory blood pressure monitoring (ABPM) studies were performed to define the
antihypertensive activity and the tolerability of lercanidipine. a new longacting …

The Latin American Study of Lacidipine in Hypertension (LASTLHY) was carried out in
twelve clinical centres situated in Argentina, Brazil, Colombia, Mexico and Venezuela. The …

Objective: The aim was to review the clinical safety profile of lacidipine with the help of the
rather comprehensive datafile of the manufacturer-a novel approach which may be of some …

The pharmacokinetic and clinical characteristics of a once-daily formulation of diltiazem are
described. In a 20 subject, 5 day, steady-state pharmacokinetic study, 10 and 240 mg of …

The aim of this study was to compare the antihypertensive efficacy and tolerability of
lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in …

We compared the safety of a new dihydropyridine calcium entry Mocker, isradipine, with an
equipotent dose of diltiazem in 174 mild hypertensives (diastolic blood pressure [DBP] 95 to …